SCYX (SCYNEXIS) Receipts from Customers

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SCYX SCYNEXIS Inc SCYX
40 GF Score
Price $5.09
GF Value $17.37
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is SCYNEXIS Receipts from Customers?

Receipts from Customers only applicable to companies reporting Cash Flow from Operations in direct method.

SCYX
40GF Score
SCYNEXIS Inc SCYX
Receipts from Customers is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is SCYNEXIS (SCYX) Overvalued in 2026?

Based on GuruFocus' analysis, SCYNEXIS stock appears to be undervalued. The current stock price of $5.09 is trading 70.7% below its estimated GF Value™ of $17.37. GuruFocus considers SCYNEXIS to be Possible Value Trap.

Key valuation signals for SCYX:

  • Receipts from Customers:
  • GF Value™: $17.37 vs. price of $5.09 (70.7% below fair value)
  • GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the SCYX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SCYNEXIS Business Description

Other Exchanges 0L49:UK135:Germany
Address 1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
40GF Score

Get the complete analysis for SCYX

Receipts from Customers is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.09
Price
$17.37
GF Value